Mylan Makes Decision On Potential First Botox Biosimilar

Launch In US By 2025 Has Been Mooted

 
• By Dean Rudge

Mylan first announced plans to develop a biosimilar of the Botox cosmetic and therapeutic brands back in 2018 through an alliance with Revance Therapeutics. More than two years later, a verdict has been reached by the company.

Young adult woman walking up the stairs with sun sport background.
Mylan will progress with plans to develop biosimilar Botox with Revance • Source: Shutterstock

More from Biosimilars

More from Products